Effect of decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消积方) plus chemoembolization on primary liver cancer in patients

doi:10.19852/j.cnki.jtcm.2022.03.011

Abstract

Abstract:

OBJECTIVE: To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消积方, FJXF) plus chemoembolization (TACE) on primary liver cancer (PLC) in patients, and study the underlying mechanism.

METHODS: Patients with PLC who met the inclusion criteria were randomized into case group and control group. The case group was treated with FJXF combined with TACE. The control group was treated with TACE alone. The short-term clinical effect was evaluated; liver biochemistry, liver function index and multidrug resistance-associated indicators were detected.

RESULTS: FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group (83.3% vs 61.1%). There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group, while no difference between the two groups. The same trend can be observed for transaminase and direct bilirubin in both groups. In the case group, it showed a significant increase for albumin at 8 weeks after treatment, while no change in the control group. Multidrug resistance-associated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group.

CONCLUSIONS: FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC. The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF. Additionally, FJXF didn’t increase the risk of liver damage in the combined therapy.

Key words: liver neoplasms, ATP binding cassette transporter,subfamily B,member 1, chemoembolization,therapeutic, Fuzheng Jiedu Xiaoji formula

WU Tong, YANG Zhiyun, YANG Yuying, JIANG Yuyong, MENG Peipei, LIU Huimin, TIAN Yehong, ZHANG Qiaoli. Effect of decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消积方) plus chemoembolization on primary liver cancer in patients[J]. Journal of Traditional Chinese Medicine, 2022, 42(3): 446-450.

Figures/Tables 4

References 23

1	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394-424. DOI URL
2	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7-30. DOI URL
3	Zhou X, Ding J, Li H, et al. Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma. J Cell Mol Med 2020; 24:4298-311. DOI URL
4	Gu LL, Liu HM, Zhou XB, et al. Efficacy analysis of integrative therapy based on Fuzheng Jiedu Xiaoji formula for primary liver cancer. J Tradit Chin Med 2014; 55:576-9.
5	Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). LIVER CANCER 2018; 7:235-260 DOI URL
6	Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatol 2018; 68:723-50. DOI URL
7	Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol 2016; 25:74-85. DOI URL
8	Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21:10327-35. DOI URL
9	Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update and clarification: grom the RECIST committee. Eur J Cancer 2016; 62:132-7. DOI URL
10	Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett 2018; 412:283-8. DOI URL
11	Lurje I, Czigany Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma - a multidisciplinary approach. Int J Mol Sci 2019; 20.
12	Cyranoski D. China embraces precision medicine on a massive scale. Nat 2016; 529:9-10.
13	Chen QF, Wu PH, Huang T, et al. Efficacy of treatment regimens for advanced hepatocellular carcinoma: a network Meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019; 98:e17460. DOI URL
14	Wan YM, Li YH, Xu ZY, et al. The effect of transarterial chemoembolization in combination with Kang’ai injection on patients with intermediate stage hepatocellular carcinoma: a prospective study. Integr Cancer Ther 2017; 17:477-85. DOI URL
15	Chen J, Zhang SL. Study of liver function impairment after TACE in liver cancer. Shi Yong Lin Chuang Yi Yao Za Zhi 2017; 21:202-4.
16	Ma MX, Sun XL, Guo YG, et al. Effect of TACE on liver function indexes in patients with primary liver cancer. Hainan Yi Xue Yuan Xue Bao 2017; 23:1705-8.
17	Zhang SW, Lan Y, Sun YM. Effect of hepatic artery chemoembolization on hepatic function in the treatment of hepatic malignancy. Lin Chuang Yi Yao Wen Xian Za Zhi 2017; 4:1011.
18	Martin S, Fako V, Dang H, et al. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res 2020; 39.
19	Buschauer S, Koch A, Wiggermann P, et al. Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro. Oncol Lett 2018; 15:4635-40.
20	Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006; 13:1859-76. DOI URL
21	Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2017; 9:808-14. DOI URL
22	Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992; 43:95-102. PMID
23	Tian QE, De LH, Yan M, et al. Effects of Astragalus poly-saccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro. BMC Com-plement Altern Med 2012; 12:94.

Group	Case group	Control group	P value
Gender (M/F, n)	26/10	30/6	0.257
Age (years, $\bar{x}\pm s$)	44.5±3.2	43.9±3.3	0.482
Hepatitis B [n (%)]	32 (88.90)	31 (86.10)	0.722
Liver cirrhosis [n (%)]	32 (88.90)	33 (91.70)	0.691
AFP positive [n (%)]	28 (77.80)	29 (80.60)	0.772
Child-Pugh rating [n (%)]			0.743
Class A	30 (83.33)	31 (86.11)	-
Class B	6 (16.67)	5 (13.89)	-
Number of lesions [n (%)]			0.722
Single	5 (13.89)	4 (11.11)	-
Multiple	31 (86.11)	32 (88.89)	-
Location of the lesion [n (%)]
Left lobe	12 (33.33)	15 (41.67)	0.465
Right lobe	10 (27.78)	9 (25.00)	0.789
Both lobes	14 (38.89)	12 (33.33)	0.624

Group	Case group	Control group	P value
Gender (M/F, n)	26/10	30/6	0.257
Age (years, $\bar{x}\pm s$)	44.5±3.2	43.9±3.3	0.482
Hepatitis B [n (%)]	32 (88.90)	31 (86.10)	0.722
Liver cirrhosis [n (%)]	32 (88.90)	33 (91.70)	0.691
AFP positive [n (%)]	28 (77.80)	29 (80.60)	0.772
Child-Pugh rating [n (%)]			0.743
Class A	30 (83.33)	31 (86.11)	-
Class B	6 (16.67)	5 (13.89)	-
Number of lesions [n (%)]			0.722
Single	5 (13.89)	4 (11.11)	-
Multiple	31 (86.11)	32 (88.89)	-
Location of the lesion [n (%)]
Left lobe	12 (33.33)	15 (41.67)	0.465
Right lobe	10 (27.78)	9 (25.00)	0.789
Both lobes	14 (38.89)	12 (33.33)	0.624

Group	n	CR	PR	SD	PD	DCR
Case	36	5 (18.89)	19 (25.78)	6 (16.67)	6 (16.67)	30 (83.30)^a
Control	36	2 (5.56)	16 (44.45)	4 (11.11)	14 (38.89)	22 (61.10)

Group	n	CR	PR	SD	PD	DCR
Case	36	5 (18.89)	19 (25.78)	6 (16.67)	6 (16.67)	30 (83.30)^a
Control	36	2 (5.56)	16 (44.45)	4 (11.11)	14 (38.89)	22 (61.10)

Item	Case group (n =36)			Control group (n =36)
Item	Before treatment	1 week after treatment	8 weeks after treatment	Before treatment	1 week after treatment	8 weeks after treatment
ALT	35.00±2.27	42.84±2.55^a	36.22±2.93	33.42±2.61	43.02±3.74^a	34.55±2.86
AST	41.88±2.54	47.11±2.98^a	43.16±2.96	40.96±2.79	48.14±3.51^a	42.29±2.96
DBIL	5.63±1.62	7.47±1.64^a	6.25±0.99	5.39±1.35	7.04±1.03^a	5.93±0.92
AFP	124.35±100.00	NA	49.78±28.89^a	140.82±109.05	NA	64.83±42.78^a
PAB	316.4±21.93	307.50±16.52	309.2±20.41	315.9±20.72	233.6±31.25^a	307.10±17.71
ALB	32.10±1.87	32.94±1.73	39.87±2.28^a	32.26±1.68	31.89±1.70	32.92±1.51
INR	1.09±0.11	1.14±0.09	1.07±0.13	1.13±0.11	1.17±0.09	1.16±0.08

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us